RecruitingPHASE2, PHASE3NCT07003386

Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke

Studying Androgen insensitivity syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Yueyang Integrated Medicine Hospital
Principal Investigator
Chunxiang Chen
Shanghai Yueyang Integrated Medicine Hospital
Intervention
Galantamine(drug)
Enrollment
66 target
Eligibility
18-85 years · All sexes
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07003386 on ClinicalTrials.gov

Other trials for Androgen insensitivity syndrome

Additional recruiting or active studies for the same condition.

See all trials for Androgen insensitivity syndrome

← Back to all trials